Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048624 | 0.93 | SCN9A (0.37) | GAASCN9A | |
| SCHEMBL17048570 | 0.92 | SCN9A (0.37) | GAASCN9A | |
| SCHEMBL17048622 | 0.92 | SCN9A (0.34) | GAASCN9AALDH1A1 | |
| SCHEMBL17048717 | 0.90 | SCN9A (0.36) | GAASCN9A | |
| SCHEMBL18882664 | 0.90 | SCN9A (0.35) | GAASCN9A | |
| SCHEMBL17048565 | 0.89 | SCN9A (0.39) | GAASCN9AKDM4EALDH1A1 | |
| SCHEMBL17048705 | 0.89 | SCN9A (0.35) | GAASCN9AKDM4EALDH1A1TDP1 | |
| SCHEMBL17048592 | 0.88 | SCN9A (0.39) | SCN9A | |
| SCHEMBL17048639 | 0.88 | SCN9A (0.34) | GAASCN9A | |
| SCHEMBL17048582 | 0.86 | RORC (0.38) | GAASCN9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | TAS2R14 1027/4885GAA 1797/4885SCN9A 29/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | TAS2R14 1241/4885GAA 1714/4885SCN9A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.